Likewise, although p53 activators nutlin‐3 (5 μm), tenovin‐1 (10 μm), or nutlin‐3/tenovin‐1 in combination with doxorubicin treatment increased p53 protein levels in renal cancer cell lines, they did not promote the upregulation of DAPK protein expression (Fig. 5K,L,N,O). The gene discussed is TP53; the disease is renal carcinoma.